Parabilis director holds option on 16,245 shares

Q: What insider position did PBLS director Craig Tendler report on this Form 3?

Craig Tendler reported holding a stock option covering 16,245 shares of Parabilis Medicines, Inc. common stock. The option has an exercise price of $2.42 per share and an expiration date of March 19, 2035, held as a direct ownership position.

Q: What are the vesting terms of Craig Tendler’s stock option in PBLS?

The filing states that 25% of the option shares vested and became exercisable on January 31, 2026. The remaining shares vest in 36 equal monthly installments thereafter, each installment subject to Craig Tendler’s continued service on the applicable vesting date.

Q: Does the Form 3 for PBLS report any insider stock purchases or sales by Craig Tendler?

No purchases or sales are reported. The Form 3 lists a holding of a stock option to buy 16,245 shares of common stock, with no buy or sell transaction code indicated and no shares acquired or disposed in this filing.

Q: Is Craig Tendler a director or officer of PBLS according to this Form 3?

The Form 3 identifies Craig Tendler as a director of Parabilis Medicines, Inc. It does not list him as an officer or ten percent owner, and no officer title is provided in the filing.

Parabilis Medicines, Inc. (symbol PBLS) reported the initial equity holdings of director Craig Tendler in a Form 3.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Parabilis Medicines, Inc. (symbol PBLS) reported the initial equity holdings of director Craig Tendler in a Form 3. Tendler holds a stock option to purchase 16,245 shares of Parabilis Medicines common stock at an exercise price of $2.42 per share, expiring on March 19, 2035.

According to the vesting terms, 25% of the shares subject to this option vested and became exercisable on January 31, 2026, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to Tendler’s continued service on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tendler Craig

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) ^F1	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 16,245 contracts (Direct)

Footnotes (1)

F1. 25% of the shares subject to this option vested and became exercisable on January 31, 2026 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Underlying option shares: 16,245 shares Exercise price: $2.42 per share Option expiration date: March 19, 2035 +2 more

5 metrics

Underlying option shares 16,245 shares Shares of Parabilis Medicines, Inc. common stock underlying the reported stock option holding

Exercise price $2.42 per share Exercise price of the stock option held by director Craig Tendler

Option expiration date March 19, 2035 Expiration date of the reported stock option

Initial vested portion 25% Portion of option shares that vested and became exercisable on January 31, 2026

Remaining vesting schedule 36 monthly installments Unvested option shares vest in 36 equal monthly installments after January 31, 2026

Key Terms

Stock Option (right to buy), exercise price, underlying security, vested and became exercisable, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"exercisePrice: 2.4200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

vested and became exercisable financial

"25% of the shares subject to this option vested and became exercisable"

monthly installments financial

"remainder vesting in thirty-six (36) equal monthly installments"

Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did PBLS director Craig Tendler report on this Form 3?

Craig Tendler reported holding a stock option covering 16,245 shares of Parabilis Medicines, Inc. common stock. The option has an exercise price of $2.42 per share and an expiration date of March 19, 2035, held as a direct ownership position.

What are the vesting terms of Craig Tendler’s stock option in PBLS?

The filing states that 25% of the option shares vested and became exercisable on January 31, 2026. The remaining shares vest in 36 equal monthly installments thereafter, each installment subject to Craig Tendler’s continued service on the applicable vesting date.

What is the exercise price and expiration date of Craig Tendler’s PBLS option?

The stock option reported by Craig Tendler has an exercise price of $2.42 per share and an expiration date of March 19, 2035. The underlying security is Parabilis Medicines, Inc. common stock.

Does the Form 3 for PBLS report any insider stock purchases or sales by Craig Tendler?

No purchases or sales are reported. The Form 3 lists a holding of a stock option to buy 16,245 shares of common stock, with no buy or sell transaction code indicated and no shares acquired or disposed in this filing.

Is Craig Tendler a director or officer of PBLS according to this Form 3?

The Form 3 identifies Craig Tendler as a director of Parabilis Medicines, Inc. It does not list him as an officer or ten percent owner, and no officer title is provided in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/25/2026 - 06:06 PM EDT Accepted by SEC EDGAR 08/25/2026 - 06:05 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tendler Craig

(Last)

(First)

(Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE

MASSACHUSETTS

02140

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/22/2026

3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	03/19/2035	Common Stock	16,245	$2.42	D

Explanation of Responses:

1. 25% of the shares subject to this option vested and became exercisable on January 31, 2026 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Teresa Jurgensen, Attorney-in-Fact	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR